SCHEMBL2432469

SCHEMBL2432469

CCOC(=O)Cc1ccc(NC(=O)c2cn(C)c3ccccc23)c(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NR4A2 P43354 1/20 0.43
CNR2 P34972 2/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 3/20 0.42
MITF O75030 1/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CNR1 P21554 1/20 0.42
HTR2C P28335 1/20 0.42
CREBBP Q92793 1/20 0.41
MAOB P27338 2/20 0.41
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14626644 0.87 KMT2A (0.46) ALDH1A1NR4A2CNR2KMT2ALMNA
SCHEMBL2433993 0.87 LMNA (0.47) ALDH1A1NR4A2CNR2KMT2ALMNA
SCHEMBL14591787 0.84 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2NR4A2CNR2KMT2A
SCHEMBL2429129 0.82 ITGB1 (0.55) ALDH1A1NR4A2KMT2ALMNAMITF
SCHEMBL3579447 0.80 ITGB1 (0.56) ALDH1A1NR4A2KMT2ALMNAMITF
SCHEMBL71948 0.80 RAB9A (0.48) SMN1; SMN2NR4A2CNR2KMT2ALMNA
SCHEMBL72718 0.80 MAPT (0.57) ALDH1A1NR4A2KMT2ALMNAMAPT
SCHEMBL27579971 0.78 HTR2C (0.46) ALDH1A1NR4A2CNR2KMT2ALMNA
SCHEMBL14505040 0.77 MAPT (0.45) NR4A2CNR2KMT2ALMNAMAPT
SCHEMBL92369 0.73 RAB9A (0.64) ALDH1A1SMN1; SMN2NR4A2KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
CN-100471838-C VLA-4 inhibitors DAIICHI SEIYAKU CO (JP) 2009-03-25 CN disclosed
CN-100396680-C Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2008-06-25 CN disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 CN disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 CN disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ALDH1A1 981/4885SMN1; SMN2 3702/4885NR4A2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.